TransCode Therapeutics, Inc. filed a Form 8-K on October 28, 2026, disclosing that its board of directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the company and its oncology portfolio.

Key Highlights

  • Board action: The board of directors has initiated a formal strategic process, according to the filing.
  • Stated objective: The process is designed to "evaluate opportunities designed to maximize the value of the Company and its oncology portfolio," as the filing states.
  • Lead asset named: The filing specifically identifies TTX-MC138 as the company's lead product candidate within the oncology portfolio under review.
  • Announcement date: The press release announcing the strategic process was issued on October 28, 2026.
  • Exchange listing: The company's common stock, par value $0.0001 per share, trades on NASDAQ:RNAZ.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.

TransCode Therapeutics Discloses Formal Strategic Review Focused on TTX-MC138

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a Delaware-incorporated company headquartered at 6 Liberty Square, #2382, Boston, Massachusetts 02109, filed a current report with the SEC on October 28, 2026, under Item 8.01 (Other Events). The filing reported that the company's board of directors has initiated a formal strategic process centered on the company and its oncology portfolio.

According to the filing, the strategic process is intended to "evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138." The disclosure does not describe the specific types of opportunities under consideration, nor does it set a timeline or outcome for the process. The company issued a press release on the same date, which is attached as Exhibit 99.1 and incorporated by reference into the filing.

The report was signed by Philippe P. Calais, Chief Executive Officer, on behalf of TransCode Therapeutics, Inc. The company confirmed it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. No financial statements were included in this filing.

What Was Disclosed

TransCode Therapeutics disclosed via an October 28, 2026 Form 8-K that its board has launched a formal strategic process to evaluate value-maximizing opportunities for the company and its oncology portfolio, including lead candidate TTX-MC138.